Abstract
Due to the declining instances of organ donation, total artificial heart (TAH) therapy is of increasing importance for the management of end-stage biventricular heart failure. We introduce the currently most important established and novel TAH systems (SynCardia, CARMAT, ReinHeart, BiVACOR), report clinical outcomes and discuss technical requirements for the successful implementation of TAH therapy as an alternative to cardiac transplantation.
Author Statement
Research funding: Authors state no funding involved.
Conflict of interest: The authors have no conflict of interest.
Informed consent: Informed consent is not applicable.
Ethical approval: The conducted research is not related to either human or animals use.
Author contributions
Sotirios Spiliopoulos and Vera Hergesell wrote the manuscript, Andrae Wasler revised the manuscript, Otto Dapunt revised the manuscript and gave final approval.
References
[1] Slepian MJ, Copeland JG. The total artificial heart in refractory cardiogenic shock: saving the patient versus saving the heart. Nat Clin Pract Cardiovasc Med 2008;5:64–5.10.1038/ncpcardio1085Search in Google Scholar PubMed
[2] Morshuis M, Reiss N, Arusoglu L, Tenderich G, Körfer R, El-Banayosy A. Implantation of CardioWest total artificial heart for irreversible acute myocardial infarction shock. Heart Surg Forum 2007;10:E251–6.10.1532/HSF98.20070706Search in Google Scholar PubMed
[3] Spiliopoulos S, Koerfer R, Tenderich G. A first step beyond traditional boundaries: destination therapy with the Syncardia total artificial heart. Interact Cardiovasc Thorac Surg 2014;18:855–6.10.1093/icvts/ivu065Search in Google Scholar PubMed
[4] Copeland J. Syncardia total artificial heart: update and future. Tex Heart Inst J 2013;40:587–8.Search in Google Scholar PubMed
[5] Ryan TD, Jefferies JL, Zafar F, Lorts A, Morales DL. The evolving role of the total artificial heart in the management of end-stage congenital heart disease and adolescents. ASAIO J 2015;61:8–14.10.1097/MAT.0000000000000156Search in Google Scholar PubMed
[6] Spiliopoulos S, Guersoy D, Dimitriou AM, Koerfer R, Tenderich G. Implantation technique of the 50-cm3 SynCardia total artificial heart: does size make a difference? Multimed Man Cardiothorac Surg 2015;2015. pii: mmv029. doi: 10.1093/mmcts/mmv029.10.1093/mmcts/mmv029Search in Google Scholar PubMed
[7] Copeland J, Copeland H, Gustafson M, Mineburg N, Covington D, Smith RG, et al. Experience with more than 100 total artificial heart implants. J Thorac Cardiovasc Surg 2012;143:727–34.10.1016/j.jtcvs.2011.12.002Search in Google Scholar PubMed
[8] Spiliopoulos S, Dimitriou AM, Guersoy D, Koerfer R, Tenderich G. Expanding applicability of total artificial heart therapy: the 50 cc Syncardia total artificial heart. Ann Thorac Surg 2015;100:e55–7.10.1016/j.athoracsur.2015.04.010Search in Google Scholar PubMed
[9] Torregrossa G, Morshuis M, Varghese R, Hosseinian L, Vida V, Tarzia V, et al. Results with SynCardia total artificial heart beyond 1 year. ASAIO J 2014;60:626–34.10.1097/MAT.0000000000000132Search in Google Scholar PubMed
[10] Copeland JG, Smith RG, Arabia FA, Nolan PE, Sethi GK, Tsau PH, et al. Cardiac replacement with a total artificial heart as a bridge to transplantation. N Engl J Med 2004;351:859–67.10.1056/NEJMoa040186Search in Google Scholar PubMed
[11] Latrémouille C, Duveau D, Cholley B, Zilberstein L, Belbis G, Boughenou MF, et al. Animal studies with the Carmat bioprosthetic total artificial heart. Eur J Cardiothorac Surg 2015;47:e172–8.10.1093/ejcts/ezv010Search in Google Scholar PubMed
[12] Ménard J. Keys to the success of the CARMAT project? Med Sci (Paris) 2014;30:204–5.10.1051/medsci/20143002020Search in Google Scholar PubMed
[13] Jansen P, van Oeveren W, Capel A, Carpentier A. In vitro haemocompatibility of a novel bioprosthetic total artificial heart. Eur J Cardiothorac Surg 2012;41:e166–72.10.1093/ejcts/ezs187Search in Google Scholar PubMed
[14] Carpentier A, Latrémouille C, Cholley B, Smadja DM, Roussel JC, Boissier E, et al. First clinical use of a bioprosthetic total artificial heart: report of two cases. Lancet 2015;386:1556–63.10.1016/S0140-6736(15)60511-6Search in Google Scholar PubMed
[15] Latremouille C, Carpentier A, Leprince P, Roussel JC, Cholley B, Boissier E, et al. A bioprosthetic total artificial heart for end-stage heart failure: results from a pilot study. J Heart Lung Transplant 2018;37:33–7.10.1016/j.healun.2017.09.002Search in Google Scholar PubMed
[16] Koerfer R, Spiliopoulos S, Finnochiaro T, Guersoy D, Tenderich G, Steinseifer U, et al. Paving the way for destination therapy of end-stage biventricular heart failure: the reinheart-total-artificial heart concept. Eur J Cardiothorac Surg 2014;46:935–6.10.1093/ejcts/ezu317Search in Google Scholar PubMed
[17] Laumen M, Finnochiaro T, Cuenca E, Guersoy D, Spiliopoulos S, Tenderich G, et al. A novel total artificial heart for destination therapy: in-vitro and in-vivo study. Biomed Tech 2013;58(Suppl. 1). DOI 10.1515/bmt-2013-4373.10.1515/bmt-2013-4373Search in Google Scholar PubMed
[18] Unthan K, Graef F, Laumen M, Finocchiaro T, Sommer C, Lanmüller H, et al. Design and evaluation of a fully implantable control unit for blood pumps. Biomed Res Int 2015;2015:257848.10.1155/2015/257848Search in Google Scholar PubMed PubMed Central
[19] Schmitz S, Unthan K, Sedlaczek M, Wald F, Finocchiaro T, Spiliopoulos S, et al. Prototype development of an implantable compliance chamber for a total artificial heart. Artif Organs 2016;41:122–9.10.1111/aor.12738Search in Google Scholar PubMed
[20] Timms D, Fraser J, Hayne M, Dunning J, McNeil K, Pearcy M. The Bivacor rotary biventricular assist device: concept and in vitro investigation. Artif Organs 2008;32:816–9.10.1111/j.1525-1594.2008.00633.xSearch in Google Scholar PubMed
[21] Greatrex NA, Timms DL, Kurita N, Palmer EW, Masuzawa T. Axial magnetic bearing developement for the Bivacor rotary BIVAD/TAH. IEEE Trans Biomed Eng 2010;57:714–21.10.1109/TBME.2009.2033389Search in Google Scholar PubMed
[22] Pauls JP, Stevens MC, Schummy E, Tansley G, Fraser JF, Timms D, et al. In vitro comparison of active and passive physiological control systems for biventricular assist devices. Ann Biomed Eng 2016;44:1370–80.10.1007/s10439-015-1425-1Search in Google Scholar PubMed
[23] Ng BC, Smith PA, Nestler F, Timms D, Cohn WE, Lim E, et al. Application of adaptive starling-like controller to total artificial heart using dual rotary blood pumps. Ann Biomed Eng 2016;45:567–79.10.1007/s10439-016-1706-3Search in Google Scholar PubMed
[24] Shah KB, Thanavaro KL, Tang DG, Quader MA, Mankad AK, Tchoukina I, et al. Impact of INTERMACS profile on clinical outcomes for patients supported with the total artificial heart. J Card Fail 2016;22:913–20.10.1016/j.cardfail.2016.04.016Search in Google Scholar PubMed
[25] Crow S, John R, Boyle A, Shumway S, Liao K, Colvin-Adams M, et al. Gastrointestinal bleeding rates in recipients of nonpulsatile and pulsatile left ventricular assist devices. J Thorac Cardiovasc Surg 2009;137:208–15.10.1016/j.jtcvs.2008.07.032Search in Google Scholar PubMed
[26] Uriel N, Pak SW, Jorde UP, Jude B, Susen S, Vincentelli A, et al. Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation. J Am Coll Cardiol 2010;56:1207–13.10.1016/j.jacc.2010.05.016Search in Google Scholar PubMed
[27] Klovaite J, Gustafsson F, Mortensen SA, Sander K, Nielsen LB. Severely impaired von Willebrand factor-dependent platelet aggregation in patients with a continuous-flow left ventricular assist device (HeartMate II). J Am Coll Cardiol 2009;53:2162–7.10.1016/j.jacc.2009.02.048Search in Google Scholar PubMed
©2019 Walter de Gruyter GmbH, Berlin/Boston
